Simultaneous occurrence of bilateral retroperitoneal neuroblastoma and bifocal malignant mixed germ cell tumor in a pediatric patient with 16p11.2 microdeletion syndrome: a case report

Central nervous system germ cell tumors are rare intracranial neoplasms that predominantly occur in pediatric populations and exhibit characteristics similar to those of gonadal and extragonadal germ cell tumors. Neuroblastoma (NB) represents the most common type of extracranial solid tumor in children, typically arising in tissues with sympathetic innervation. We present a case involving a 14-year-old male patient diagnosed with bilateral intracranial mixed germ cell tumors and concurrent bilateral retroperitoneal ganglioneuroblastoma. To the best of our knowledge, this is the first documented instance of the co-occurrence of these two distinct neoplastic entities. Additionally, Whole-exome sequencing (WES) of the blood sample identified a chromosomal deletion consistent with the 16p11.2 microdeletion syndrome. Furthermore, a heterozygous missense variant in the ALK gene (p. Arg1275Gln) was identified.

1 Introduction

Central nervous system germ cell tumors constitute a relatively infrequent category of intracranial neoplasms, predominantly affecting younger individuals. In the United States, the incidence rate is 0.23 per 100,000 individuals. In contrast, the incidence rate of these tumors within Asian nations varies between 0.45 and 0.78 per 100,000 individuals (1–4). According to the 2016 guidelines published by the World Health Organization, central nervous system germ cell tumors are classified into seven distinct types, with mixed germ cell tumors being a significant constituent (5). Neuroblastoma represents the most prevalent form of extracranial solid malignancy among pediatric populations. It originates from progenitor cells located within the neural crest during embryogenesis and has the capacity to emerge throughout the sympathetic nervous system, exhibiting a particular propensity for the adrenal glands (6, 7). The 16p11.2 deletions represent one of the most prevalent causes of neurodevelopmental disorders and autism spectrum disorder, with an occurrence rate of approximately 1 in 2000. Individuals possessing these deletions frequently exhibit a spectrum of clinical manifestations, including delays in early neurodevelopmental milestones. They often experience specific deficits in speech and phonology, language proficiency, diminished cognitive abilities, challenges with motor coordination, and are prone to autism, seizures, and obesity (8).

Previous oncology studies have observed this deletion in germinoma (4), acute myeloid leukemia (9), and neuroblastoma (10), hinting at an oncogenic context. MAPK3 is located within the chromosomal region 16p11.2 and encodes extracellular signal-regulated kinase 1 (ERK1). In a mouse model of autism, the 16p11.2 microdeletion disrupts the balance between neural progenitor cell proliferation and differentiation through dysregulation of the ERK–MAPK signaling cascade, resulting in aberrant brain architecture and behavioral impairments (11). However, the impact on other cancers remains unknown.

In this report, we documented a rare instance of a pediatric patient with 16p11.2 microdeletion syndrome presenting with the simultaneous occurrence of bilateral retroperitoneal neuroblastoma and bifocal malignant mixed germ cell tumor.

2 Case presentation

A 14-year-old boy was admitted to the local hospital with a sudden headache, and vomiting and weakness of limbs for 3 hours. Cranial magnetic resonance imaging (MRI) examination of the head showed that the pineal region tumor was complicated with hydrocephalus in the third ventricle, bilateral lateral ventricles, and white matter edema in the ventricle: considering a germ cell tumor, lateral ventricle puncture and external drainage were performed under general anesthesia. Cranial computed tomography showed an epidural hematoma on the right forehead. The patient received brain hematoma removal, other cranial nerve decompression, and skull repair. The family members of the children requested to be transferred to a higher-level hospital for further diagnosis and treatment, so they were transferred to our hospital by ambulance. Physical examination can find language and learning impairment, intellectual disability, macrocephaly, dysmorphic facial features, including forehead protrusion, strabismus, wide mouth, and wide nose. There was no hepatosplenomegaly or lymphadenopathy. The child has a documented history of delayed language acquisition, intellectual impairment, and academic performance challenges. Both parents and the two older sisters have no reported medical conditions and are currently in good health.

The patient underwent cranial MRI, which revealed abnormal signal foci in the suprasellar cistern and pineal region. Specifically, one focus measured 1.0 × 1.5 × 0.9 cm in the suprasellar cistern, while another measured 1.5 × 1.7 × 2.0 cm in the pineal region, suggestive of reproductive tumors (Figure 1). Additionally, the patient underwent abdominothoracic computed tomography. A mass-like shadow with mixed density was observed in the right retroperitoneal (adrenal) region, measuring approximately 9.7 × 4.4 × 6.7 cm. Furthermore, multiple nodular lesions with heterogeneous density were detected in the left retroperitoneal area, with the largest lesion, measuring approximately 2.2 × 1.8 cm, located inferior to the left renal artery (Figure 2).

Figure 1

Figure 1. Cranial MRI manifestations of a mixed germ cell tumor in the suprasellar region (A-D) and pineal region (E-F) . On T1-weighted imaging sequences, the tumor displayed iso- to slightly hypointense signals (A, E). On T2-weighted imaging (B, F) and fluid-attenuated inversion recovery (FLAIR) sequences, it exhibited iso- to slightly hyperintense signals. Heterogeneous enhancement was observed on post-contrast images (D, H).

Figure 2

Figure 2. Abdominal CT findings of ganglioneuroblastoma in the same pediatric patient as depicted in Figure 1, involving the right (A-C) and left (D-F) retroperitoneal regions. On non-contrast CT scans ((A, D); lesions indicated by arrows), heterogeneous soft-tissue density masses were identified in the retroperitoneal space, with irregular calcifications observed in both cases. Contrast-enhanced CT scans demonstrated mild heterogeneous enhancement of the masses during the arterial phase ((B, E); arrows) and venous phase ((C, F); arrows).

The biochemical endocrine examination showed the following results: follicle-stimulating hormone (FSH) 0.46 mIU/mL (normal range 1.27-19.46 mIU/mL), luteinising hormone (LH) 0.25 mIU/mL (normal range 1.24-8.62 mIU/mL), total testosterone 907.46 ng/dL (normal range 350-1,070 ng/dL), prolactin 55.28 ng/mL (2.64-13.3 ng/mL), thyroid-stimulating hormone (TSH) 4.517µIU/mL (normal range 0.34-5.6 µIU/mL) and free triiodothyronine 4.62 pmol/L (normal range 3.1-7.7pmol/L), free thyroxine (FT4) 11.08pmol/L (normal range 7.3-22.0 pmol/L), under 50µg/day of levothyroxine, CEA 1.78 ng/mL (normal range 0-5.0 ng/mL), His growth hormone (GH) 0.082ng/mL, analytical tests revealed an adrenocorticotropic hormone (ACTH) plasmatic level at 8AM of 19.3pg/mL, and a cortisol plasmatic level at 0AM of 10.23µg/dL, 8AM of 13.40µg/dL, 4PM 6.92µg/dL (normal range 3.35–11.3µg/dL), Tumor markers alpha-fetoprotein was not elevated in the serum and cerebrospinal fluid, the serum β-subunit of human chorionic gonadotropin (β-hCG) 121.75 mIU/mL (normal range 0–5 mIU/mL), β-hCG in cerebrospinal fluid was significantly elevated in the initial work-up of 430.31 mIU/mL, neuron-specific enolase was normal, The key laboratory parameters were presented in Table 1.

Table 1

Table 1. Key laboratory parameters evaluation.

Considering the possibility that the child harbors tumors of two distinct origins and exhibits symptoms indicative of intracranial hypertension, priority was given to managing the life-threatening intracranial malignant tumor while closely monitoring the abdominal tumor. The patient underwent resection of a space-occupying lesion in the sellar region and resection of a space-occupying lesion in the pineal gland. Following surgery, hydrocortisone-based hormone replacement therapy was initiated for adrenal insufficiency management, desmopressin tablets were administered to control urine volume, and levothyroxine sodium tablets were prescribed to modulate thyroid hormone levels. Pathological immunohistochemical analysis revealed Ki-67 positivity (hotspot area 70%+), Syn (−), CD99 (+), CD34 (vascular and stromal +), S-100 (−), SALL4 (+), OCT-4 (+), INI1 (partial +), Vim (+), CK (+), Glypican (focal dot-like +), AFP (partial +), PLAP (+), CD117 (+), CD30 (−), and α-inhibin (partial weak +), findings consistent with a malignant mixed germ cell tumor. Germ cell tumor components accounted for approximately 97% of the tumors at both sites, while yolk sac tumor components constituted approximately 3% (Figure 3). The patient received chemotherapy, alternating between the CE regimen (etoposide 150 mg/m² for 3 days on days 1–3, carboplatin 600 mg/m² on day 1) and the IE regimen (ifosfamide 1.8 g/m² for 5 days on days 1–5, etoposide 100 mg/m² for 5 days on days 1–5) in the treatment protocol.

Figure 3

Figure 3. Pathological manifestations of neuroblastoma and malignant Mixed Germ Cell Tumor (A–F). (A) Germinoma tumor cells are arranged in diffuse sheets. The tumor cells exhibit clear cytoplasm and large, round nuclei with inconspicuous nucleoli. Lymphocytic infiltration is observed between the tumor cells (×100, HE staining). (B) Immunohistochemistry (IH) demonstrates OCT4 nuclear staining positivity (×200). (C) A focal component of yolk sac tumor is present. The tumor displays glandular structures (×100, HE staining). (D) Immunohistochemistry (IH) for HNF1β reveals nuclear positivity (×200). (E) Nests of neuroblasts are arranged in linear arrays within an abundant and well-differentiated Schwannian stroma. The neuroblasts within the nests exhibit good differentiation, with visible neurofibrillary processes (×100). (F) Immunohistochemistry (IH) demonstrates PHOX2B nuclear positivity in the neuroblasts.

The abdominal tumor foci were closely monitored during the initial treatment phase and demonstrated no significant changes in size. Following three cycles of chemotherapy, the patient underwent complete surgical resection of bilateral retroperitoneal masses. Pathological examination was consistent with a diagnosis of ganglioneuroblastoma, mixed type. Immunohistochemical analysis revealed Ki-67 (1%+), Chromogranin A (+), Synaptophysin (+), S-100 (+), Neuron-Specific Enolase (+), Protein Gene Product 9.5 (+), PHOX2B (+), and Nestin (+) (Figure 3). No evidence of metastasis was observed in other sites. Tissue-specific gene expression analysis confirmed the absence of N-MYC gene amplification, 1p36 gene deletion, and 11q23 gene deletion. Bone marrow aspiration and minimal residual disease (MRD) analysis were negative. The patient was diagnosed with Neuroblastoma (NB), classified as Stage L1 within the Very Low-Risk Group, in accordance with the International Neuroblastoma Risk Group Staging System (INRGSS) (12). After evaluation, it was determined that ganglioneuroblastoma does not require additional chemotherapy and can be managed effectively through close surveillance.

Treatment for intracranial germ cell tumors will proceed as planned with a combination of radiotherapy and chemotherapy. After completing four cycles of chemotherapy, the child underwent fractionated stage-based radiotherapy. First-stage: The planning target volume (PTV) for the whole ventricles and sellar region received a total dose of 36 Gy, delivered in 20 fractions at 1.8 Gy per fraction over 27 days. The planning gross tumor volume (PGTV) for the sellar region and pineal tumor bed received the same total dose regime. Second-stage: The PGTV for the sellar region and pineal tumor bed had received a boost dose of 10 Gy, delivered in 5 fractions at 2.0 Gy per fraction over 7 days. Following radiotherapy, chemotherapy was resumed, resulting in a total of six chemotherapy cycles.

Given the child’s distinctive facial features, developmental delay, and the presence of two malignancies from distinct origins, whole-exome sequencing (WES) was performed for more detailed analysis. WES revealed a heterozygous deletion of 562.08 kilobases on the short arm of chromosome 16 [arr[hg19] 16p11.2 (29 675 050–30 237 124) x1]. This finding is characteristic of the 16p11.2 microdeletion syndrome and was inherited from the father (Figure 4A). In addition, a heterozygous missense variant in the ALK gene (NM_004304.5: c.3824G>A, p. Arg1275Gln) was identified in the child’s blood. Notably, this variant was absent in the parents’ peripheral blood samples, indicating a de novo origin (Figure 4B). The ALK gene has been linked to autosomal dominant or somatic variants that confer susceptibility to neuroblastoma type 3.

Figure 4

Figure 4. (A) WES identified a heterozygous deletion of 562.08 kilobases on the short arm of chromosome 16 [arr[hg19] 16p11.2 (29 675 050–30 237 124) x1]. This deletion, characteristic of the 16p11.2 microdeletion syndrome, was inherited from the patient's father. (B) Sanger sequencing of blood samples from the patient's parents was carried out for family verification: A heterozygous missense variant in the ALK gene (NM_004304.5: c.3824G>A, p. Arg1275Gln) was identified in the blood samples. This variant was not detected in the peripheral blood of his parents, suggesting a de novo origin. .

Upon completion of all chemotherapy sessions, patients were recommended to undergo regular follow-up examinations to monitor treatment response and identify any potential recurrence or late effects. Five months post-chemotherapy, follow-up was conducted through May 2025. The patient was still alive, and two tumors had achieved complete remission. Endocrine evaluation revealed hypopituitarism, and the patient continued to receive levothyroxine and human chorionic gonadotropin (hCG) for hormone replacement. Growth hormone therapy was not initiated due to the family’s concerns regarding potential tumor recurrence. The patient’s clinical course, encompassing initial presentation, treatment, and follow-up, is summarized in Figure 5.

Figure 5

Figure 5. Clinical timeline of the patient. CE, Carboplatin, Etoposide; IE, Ifosfamide, Etoposide; CR, Complete Response.

3 Discussion

Central nervous system germ cell tumors are infrequent neoplasms among children and young adults. They are predominantly found in midline locations, particularly within the pineal and suprasellar regions (13). Approximately 20% of patients may exhibit bifocal pathologies, which simultaneously affect the pineal and suprasellar regions (14). Neuroblastoma is the most prevalent extracranial solid malignant tumor. The most frequent primary sites are the adrenal glands, celiac ganglia, as well as the superior cervical and paraspinal regions (7). Neuroblastoma has been well-documented to coexist with various malignancies, with numerous case reports highlighting its association with Wilms’ tumor. Published cases include: a 4-year-old female with synchronous Wilms tumor and ganglioneuroma (15); a 2-year-old neurofibromatosis patient presenting with Wilms tumor and ganglioneuroblastoma (16); and an infant with Fanconi anemia demonstrating concurrent neuroblastoma and nephroblastoma, Further reports describe an 11-month-old female with VACTERL syndrome and Fanconi anemia exhibiting simultaneous neuroblastoma and nephroblastoma (17), along with other cases involving infants bearing multiple severe congenital anomalies paired with synchronous neuroblastoma and nephroblastoma (18). A particularly notable case documents a patient with Wilms tumor in the right kidney and neuroblastoma in the contralateral kidney (19).

While both Wilms tumor and neuroblastoma predominantly occur sporadically, familial predisposition patterns for these malignancies have been extensively characterized in the clinical literature (20). Beyond Wilms tumor, neuroblastoma has been reported to synchronously manifest with diverse malignant neoplasms, including T-lymphoblastic lymphoma (21), Hepatoblastoma (22), Adrenocortical carcinoma (23), Clear cell sarcoma of the kidney (24), Rhabdomyosarcoma (25) and Langerhans cell histiocytosis (26). Nevertheless, no documented cases of neuroblastoma co-occurring with germ cell tumors have been reported to date. Moreover, the pathophysiological mechanisms underlying the simultaneous development of multiple tumors in pediatric patients remain largely enigmatic.

In the present case, the patient exhibited elevated human chorionic gonadotropin (hCG) in both serum and cerebrospinal fluid. It is important to clarify that exhaustive histopathological examination of the intracranial tumor revealed a mixed germ cell tumor consisting of approximately 97% germinoma and 3% yolk sac tumor, with no distinct trophoblastic or choriocarcinomatous component identified. This observation aligns with contemporary molecular evidence (27), indicating that hCG expression is an inherent capacity of germinoma cells, This expression may originate from scattered syncytiotrophoblastic giant cells or other mechanisms. Furthermore, hCGβ expression is not exclusive to choriocarcinoma but is also detected across other subtypes, including yolk sac tumors.

Germline microdeletions at 16p11.2 are known to predispose individuals to neuroblastoma, as a 550-kilobase deletion within this region is significantly overrepresented among neuroblastoma cases (10). Furthermore, these copy number variants (CNVs) correspond to a well-established microdeletion syndrome associated with an increased risk for various developmental phenotypes, including autism spectrum disorder and other neurodevelopmental disorders (8). Clinical case reports suggest an association between 16p11.2 microdeletion syndrome and the development of certain malignancies, such as acute myeloid leukemia, Endometrial cancer (28), Bifocal germinoma (4), and Wilms’ tumor (29). However, the underlying mechanisms linking 16p11.2 microdeletion syndrome to the development of these malignancies remain poorly understood.

The occurrence of two distinct primary malignant neoplasms in children represents an exceptionally rare clinical scenario. This article presents a novel case of concurrent neuroblastoma and malignant mixed germ cell tumor in a pediatric patient with 16p11.2 Microdeletion Syndrome- a previously unreported combination in medical literature.

The diagnosis of NB at age 14 in this patient is notably rare, as this tumor typically presents in early childhood (median age <2 years) (30). While uncommon, adolescent-onset NB is documented and may be associated with distinct biological behaviors (31). In the context of a genetic predisposition syndrome such as 16p11.2 microdeletion, this delayed clinical manifestation suggests that the microdeletion alone is insufficient for tumorigenesis. Instead, it likely requires a prolonged timeframe for the accumulation of cooperating somatic genetic and epigenetic events to drive clinical disease.

Mitogen-activated protein kinase 3 (MAPK3), located within the 16p11.2 chromosomal region, encodes extracellular signal-regulated kinase 1 (ERK1), which plays a central role in cell proliferation by promoting positive regulators of the cell cycle (32). In vitro studies have demonstrated that ERK1 plays a crucial role in regulating differentiation and proliferation in myeloid cells (33). It is therefore plausible that the co-occurrence of malignancies in patients with 16p11.2 microdeletion syndrome may be associated with dysregulation of ERK1-mediated control of cell proliferation. The activity of the MAPK signaling pathway is governed not only by the presence or absence of extracellular stimuli, but also by the intensity, duration, and oscillatory dynamics of the signal (34). This may contribute to the delayed onset of tumorigenesis. The delayed manifestation of tumors underscores the protracted nature of this multi-step, multifactorial accumulation process. Confirming this association and translating it into effective long-term health management for carriers will require future longitudinal cohort studies and in-depth mechanistic investigations.

Copy number aberrations involving the ALK gene are frequent genetic events in the development of neuroblastoma. ALK contributes to neuroblastoma pathogenesis, in part, through a feedforward loop between POSTN and WNT signaling (35, 36). The presence of a heterozygous missense variant in the ALK gene in this patient may represent a second hit, thereby contributing to the development of neuroblastoma.

During follow-up, the child was diagnosed with hypopituitarism and consequently required hormone replacement therapy. In patients with intracranial tumors—particularly those with lesions in the sellar or pineal regions—multimodal treatment, including chemotherapy, surgery, and radiotherapy, is commonly necessary. Both the disease itself and its treatment may compromise the hypothalamic-pituitary axis, underscoring the importance of close endocrine monitoring and timely initiation of hormone replacement therapy, which plays a critical role in improving long-term outcomes in pediatric patients.

In summary, this case has provided valuable clinical insights and practical experience. First, in children presenting with anatomically distinct tumor foci, diagnostic considerations must extend beyond metastasis to include synchronous primary malignancies. Second, when dual primary tumors are suspected, the therapeutic focus should immediately address the life-threatening lesion while instituting rigorous surveillance for the secondary tumor. Third, Histopathological biopsy constitutes the definitive method for distinguishing tumor origins. Poor therapeutic response in any lesion warrants surgical resection for diagnostic clarification. Finally, comprehensive germline testing is essential in synchronous tumor presentations, given the potential association with tumor predisposition syndromes.

Patient Perspective: Written informed consent was obtained from the patient’s legal guardian for the publication of this case report and any accompanying images. The guardian has reviewed the final manuscript and confirms that anonymized data may be used for scientific and educational purposes.

Data availability statement

The original contributions presented in the study are included in the article material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by the Ethics Committee of Hunan Children's Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin. Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author contributions

Q-XF: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. X-MZ: Data curation, Writing – review & editing, Formal Analysis, Investigation. RW: Data curation, Formal Analysis, Methodology, Writing – review & editing. X-HW: Data curation, Formal Analysis, Methodology, Writing – review & editing. H-YL: Data curation, Investigation, Validation, Writing – review & editing. H-XY: Data curation, Resources, Supervision, Validation, Writing – review & editing. W-YK: Data curation, Supervision, Writing – review & editing. B-SZ: Conceptualization, Data curation, Supervision, Writing – review & editing. M-CZ: Data curation, Resources, Supervision, Visualization, Writing – review & editing. PW: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Abbreviations

NB, Neuroblastoma. WES, Whole-exome sequencing. CE, Carboplatin, Etoposide. IE, Ifosfamide, Etoposide. CR, Complete Response.

References

1. Kang JM, Ha J, Hong EK, Ju HY, Park BK, Shin SH, et al. A nationwide, population-based epidemiologic study of childhood brain tumors in korea, 2005-2014: A comparison with United States data. Cancer Epidemiol Biomarkers Prev. (2019) 28:409–16. doi: 10.1158/1055-9965.EPI-18-0634

PubMed Abstract | Crossref Full Text | Google Scholar

2. Makino K, Nakamura H, Yano S, Kuratsu JI, and Kumamoto Brain Tumor Research Group. Incidence of primary central nervous system germ cell tumors in childhood: a regional survey in Kumamoto prefecture in southern Japan. Pediatr Neurosurg. (2013) 49:155–8. doi: 10.1159/000358806

PubMed Abstract | Crossref Full Text | Google Scholar

3. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. (2019) 21:v1–v100. doi: 10.1093/neuonc/noz150

PubMed Abstract | Crossref Full Text | Google Scholar

4. Ventura M, Gomes L, Rosmaninho-Salgado J, Barros L, Paiva I, Melo M, et al. Bifocal germinoma in a patient with 16p11.2 microdeletion syndrome. Endocrinol Diabetes Metab Case Rep. (2019) 2019. doi: 10.1093/neuonc/noz150

PubMed Abstract | Crossref Full Text | Google Scholar

5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. (2016) 131:803–20. doi: 10.1007/s00401-016-1545-1

PubMed Abstract | Crossref Full Text | Google Scholar

6. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Primers. (2016) 2:16078. doi: 10.1038/nrdp.2016.78

PubMed Abstract | Crossref Full Text | Google Scholar

7. Maris JM. Recent advances in neuroblastoma. N Engl J Med. (2010) 362:2202–11. doi: 10.1056/NEJMra0804577

PubMed Abstract | Crossref Full Text | Google Scholar

8. Chung WK, Roberts TP, Sherr EH, Snyder LG, and Spiro JE. 16p11.2 deletion syndrome. Curr Opin Genet Dev. (2021) 68:49–56. doi: 10.1016/j.gde.2021.01.011

PubMed Abstract | Crossref Full Text | Google Scholar

9. Abe K, Dowsett L, Wada R, and Hutchins K. A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome. Pediatr Blood Cancer. (2021) 68:e28764. doi: 10.1002/pbc.28764

PubMed Abstract | Crossref Full Text | Google Scholar

10. Egolf LE, Vaksman Z, Lopez G, Rokita JL, Modi A, Basta PV, et al. Germline 16p11.2 microdeletion predisposes to neuroblastoma. Am J Hum Genet. (2019) 105:658–68. doi: 10.1016/j.ajhg.2019.07.020

PubMed Abstract | Crossref Full Text | Google Scholar

11. Pucilowska J, Vithayathil J, Tavares EJ, Kelly C, Karlo JC, and Landreth GE. The 16p11.2 deletion mouse model of autism exhibits altered cortical progenitor proliferation and brain cytoarchitecture linked to the ERK MAPK pathway. J Neurosci. (2015) 35:3190–200. doi: 10.1523/JNEUROSCI.4864-13.2015

PubMed Abstract | Crossref Full Text | Google Scholar

12. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. (2009) 27:298–303. doi: 10.1200/JCO.2008.16.6876

PubMed Abstract | Crossref Full Text | Google Scholar

13. Keene D, Johnston D, Strother D, Fryer C, Carret AS, Crooks B, et al. Epidemiological survey of central nervous system germ cell tumors in Canadian children. J Neurooncol. (2007) 82:289–95. doi: 10.1007/s11060-006-9282-2

PubMed Abstract | Crossref Full Text | Google Scholar

14. Aizer AA, Sethi RV, Hedley-Whyte ET, Ebb D, Tarbell NJ, Yock TI, et al. Bifocal intracranial tumors of nongerminomatous germ cell etiology: diagnostic and therapeutic implications. Neuro Oncol. (2013) 15:955–60. doi: 10.1093/neuonc/not050

PubMed Abstract | Crossref Full Text | Google Scholar

15. Moran C, Greiner RJ, Mardam-Bey SW, Hollingsworth CL, Kulbacki E, and Wechsler DS. Synchronous occurrence of metastatic Wilms tumor and ganglioneuroma. Pediatr Blood Cancer. (2010) 55:562–5. doi: 10.1002/pbc.22553

PubMed Abstract | Crossref Full Text | Google Scholar

16. Ito F, Watanabe Y, and Ito T. Synchronous occurrence of Wilms tumor and ganglioneuroblastoma in a child with neurofibromatosis. Eur J Pediatr Surg. (1997) 7:308–10. doi: 10.1055/s-2008-1071180

PubMed Abstract | Crossref Full Text | Google Scholar

17. Berrebi D, Lebras MN, Belarbi N, Couturier J, Fattet S, Faye A, et al. Bilateral adrenal neuroblastoma and nephroblastoma occurring synchronously in a child with Fanconi’s anemia and VACTERL syndrome. J Pediatr Surg. (2006) 41:e11–14. doi: 10.1016/j.jpedsurg.2005.10.087

PubMed Abstract | Crossref Full Text | Google Scholar

18. Steward VW and Jevtic MM. Derangement of neuronal migration in a child with multiple congenital anomalies, two congenital neoplasms, without apparent chromosomal abnormalities. J Neuropathol Exp Neurol. (1979) 38:259–85. doi: 10.1097/00005072-197905000-00007

PubMed Abstract | Crossref Full Text | Google Scholar

19. Sokolova IN. A case of Wilms’ tumor and neuroblastoma of the kidneys in a child. Arkh Patol. (1989) 51:61–4.

PubMed Abstract | Google Scholar

20. Abbaszadeh F, Barker KT, McConville C, Scott RH, and Rahman N. A new familial cancer syndrome including predisposition to Wilms tumor and neuroblastoma. Fam Cancer. (2010) 9:425–30. doi: 10.1007/s10689-009-9319-8

PubMed Abstract | Crossref Full Text | Google Scholar

21. Tibout P, Livingston J, Kanwar N, Yuki KE, Shlien A, Ngan B, et al. Synchronous T-lymphoblastic lymphoma and neuroblastoma in a 3-yr-old with novel germline SMARCA4 and EZH2 variants. Cold Spring Harb Mol Case Stud. (2023) 9. doi: 10.1101/mcs.a006286

PubMed Abstract | Crossref Full Text | Google Scholar

22. Ozawa MG, Cooney T, Rangaswami A, and Hazard FK. Synchronous hepatoblastoma, neuroblastoma, and cutaneous capillary hemangiomas: A case report. Pediatr Dev Pathol. (2016) 19:74–9. doi: 10.2350/14-11-1573-CR.1

PubMed Abstract | Crossref Full Text | Google Scholar

23. Pivnick EK, Furman WL, Velagaleti GV, Jenkins JJ, Chase NA, and Ribeiro RC. Simultaneous adrenocortical carcinoma and ganglioneuroblastoma in a child with Turner syndrome and germline p53 mutation. J Med Genet. (1998) 35:328–32. doi: 10.1136/jmg.35.4.328

PubMed Abstract | Crossref Full Text | Google Scholar

24. Doshi PR, Karandikar MN, Swami RC, Singh HA, and Nimbargi RC. Dual tumor - Clear cell sarcoma of kidney with differentiating neuroblastoma: A rare case with review of literature. Indian J Pathol Microbiol. (2017) 60:111–4. doi: 10.4103/0377-4929.200047

PubMed Abstract | Crossref Full Text | Google Scholar

25. Hu JJ and Wang HM. Coexistence of orbital rhabdomyosarcoma and adrenal neuroblastic tumor in a child. Pediatr Int. (2021) 63:859–61. doi: 10.1111/ped.14504

PubMed Abstract | Crossref Full Text | Google Scholar

26. Shiohama T, Ochiai H, Hishiki T, Yoshida H, and Kohno Y. Coexistence of neuroblastoma detected on staging of Langerhans cell histiocytosis. Pediatr Int. (2014) 56:608–10. doi: 10.1111/ped.12292

PubMed Abstract | Crossref Full Text | Google Scholar

27. Takami H, Fukushima S, Fukuoka K, Suzuki T, Yanagisawa T, Matsushita Y, et al. Human chorionic gonadotropin is expressed virtually in all intracranial germ cell tumors. J Neurooncol. (2015) 124:23–32. doi: 10.1007/s11060-015-1809-y

PubMed Abstract | Crossref Full Text | Google Scholar

28. Stylianou CE, Wiggins GAR, Lau VL, Dennis J, Shelling AN, Wilson M, et al. Germline copy number variants and endometrial cancer risk. Hum Genet. (2024) 143:1481–98. doi: 10.1007/s00439-024-02707-9

PubMed Abstract | Crossref Full Text | Google Scholar

29. Mason JE, Goodfellow PJ, Grundy PE, and Skinner MA. 16q loss of heterozygosity and microsatellite instability in Wilms’ tumor. J Pediatr Surg. (2000) 35:891–896; discussion 896-897. doi: 10.1053/jpsu.2000.6911

PubMed Abstract | Crossref Full Text | Google Scholar

30. Maris JM, Hogarty MD, Bagatell R, and Cohn SL. Neuroblastoma. Lancet. (2007) 369:2106–20. doi: 10.1016/S0140-6736(07)60983-0

PubMed Abstract | Crossref Full Text | Google Scholar

31. Mazzocco K, Defferrari R, Sementa AR, Garaventa A, Longo L, De Mariano M, et al. Genetic abnormalities in adolescents and young adults with neuroblastoma: A report from the Italian Neuroblastoma group. Pediatr Blood Cancer. (2015) 62:1725–32. doi: 10.1002/pbc.25552

PubMed Abstract | Crossref Full Text | Google Scholar

32. Cargnello M and Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. (2011) 75:50–83. doi: 10.1128/MMBR.00031-10

PubMed Abstract | Crossref Full Text | Google Scholar

33. Lunghi P, Tabilio A, Dall'Aglio PP, Ridolo E, Carlo-Stella C, Pelicci PG, et al. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts. Leukemia. (2003) 17:1783–93. doi: 10.1038/sj.leu.2403032

PubMed Abstract | Crossref Full Text | Google Scholar

34. Murphy LO and Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci. (2006) 31:268–75. doi: 10.1016/j.tibs.2006.03.009

PubMed Abstract | Crossref Full Text | Google Scholar

35. Subramaniam MM, Piqueras M, Navarro S, and Noguera R. Aberrant copy numbers of ALK gene is a frequent genetic alteration in neuroblastomas. Hum Pathol. (2009) 40:1638–42. doi: 10.1016/j.humpath.2009.05.002

PubMed Abstract | Crossref Full Text | Google Scholar

36. Huang M, Fang W, Farrel A, Li L, Chronopoulos A, Nasholm N, et al. ALK upregulates POSTN and WNT signaling to drive neuroblastoma. Cell Rep. (2024) 43:113927. doi: 10.1016/j.celrep.2024.113927

PubMed Abstract | Crossref Full Text | Google Scholar